UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 29, 2017

LEXARIA BIOSCIENCE CORP.
(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code (250) 765-6424

N/A
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[   ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[   ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
[   ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[   ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b -2 of this chapter).

Emerging growth company [   ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
[   ]

- 2 -

Item 3.02        Unregistered Sales of Equity Securities

On August 29, 2017, Lexaria Bioscience Corp. (the “Company” or “Lexaria”) announced it is attending and exhibiting at the Investorshub International Cannabis Conference in Los Angeles on September 1-2, held at the JW Marriott downtown. Chris Bunka, CEO of Lexaria, will be giving a presentation on the latest technology available to benefit the cannabis industry.

On September 7-8, Lexaria is attending and exhibiting at The Institutional Capital & Cannabis Conference (East) in Miami Beach. This conference is targeted at high net worth investors, family offices and institutions as an East Coast follow up to an earlier sold-out event in California.

Lexaria has also received and executed a notice of conversion related to certain convertible debt, extinguishing a $45,000 convertible debt plus interest for 307,500 restricted common shares at the contracted conversion price of US$0.15. Lexaria has also issued 32,433 common shares to settle US$12,000 of debt to a director, at a conversion price of US$0.37 per share.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Item 7.01        Regulation FD Disclosure

A copy of the news release announcing that Lexaria will be attending two Cannabis Investment Conferences and Issuing Shares for Debt is filed as exhibit 99.1 to this current report and is hereby incorporated by reference.

Item 9.01        Financial Statements and Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LEXARIA BIOSCIENCE CORP.